Podcasts about regulatory

After decades of facing severe overfishing and cultural stigma, global shark populations are finally rebounding thanks to strict new international trade bans and expanding marine sanctuaries. Emma Varvaloucas, Executive Director of The Progress Network, shares how much our views and treatment of sharks have shifted over the last century and why there's reason for optimism. Plus: a team of 23 students in the Netherlands successfully engineered the world's first fully solar-powered ambulance to deliver off-grid medical care, Indigenous youth are reclaiming traditional face tattooing to preserve their cultural heritage, and robust conservation programs have helped two wildlife species in America bounce back from the brink of extinction.What Could Go Right? is produced by The Progress Network and Kaleidoscope.For transcripts, to join the newsletter, and for more information, visit: theprogressnetwork.orgSubscribe to our (FREE) Substack newsletter: https://theprogressnetwork.org/newsletter/Watch the podcast on YouTube: / theprogressnetworkFollow us on X, Instagram, Facebook, TikTok: @progressntwrkFollow Emma on Instagram: https://www.instagram.com/heyemmavarv/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic virus, has recently received a positive nod from an advisory committee for its Phase 1/2 trial. When combined with PD-1 checkpoint inhibitors, it holds promise for enhancing immune responses against tumors—a critical development in cancer treatment that may redefine therapeutic strategies. This advancement follows two prior FDA rejections, underscoring the multifaceted evaluation process drugs undergo before approval and demonstrating that perseverance can eventually lead to success. Meanwhile, AstraZeneca and Daiichi Sankyo have achieved a milestone with the European Union's approval of Datopotamab Deruxtecan for treating unresectable or metastatic triple-negative breast cancer (TNBC). As an antibody-drug conjugate targeting the Trop-2 protein, it offers new hope to TNBC patients who often have limited options. This approval underscores the potential of antibody-drug conjugates in oncology, supported by promising Phase 3 trial data. Regeneron Pharmaceuticals is enjoying notable revenue growth thanks to Dupixent, a monoclonal antibody addressing autoimmune and respiratory diseases. Such financial success underscores the expanding role of biologics in tackling chronic illnesses, reflecting a broader industry trend towards biologically-based treatments. In business news, Pharmanovia's licensing deal with Impact Therapeutics for Senaparib signifies strategic expansion in oncology therapeutics. Similarly, Kaigene's agreement with Taisho Pharmaceutical highlights ongoing interest in autoimmune therapies, illustrating how companies are leveraging partnerships to broaden their therapeutic horizons. Pfizer is on the brink of expanding its label for Ritlecitinib (Litfulo), a JAK3 inhibitor that showed positive results in Phase 3 trials for nonsegmental vitiligo. By targeting autoimmune pathways, this small molecule could offer new hope to vitiligo patients seeking effective treatments. Litfulo is advancing through regulatory stages following successful trials, poised to provide an oral alternative for non-segmental vitiligo—a potential game-changer that could improve patient compliance and expand treatment options beyond Incyte's Opzelura. However, not all news is positive. Novo Nordisk faced disappointment when its Ziltivekimab failed a Phase 3 trial for atherosclerotic cardiovascular disease with chronic kidney disease. Despite this setback, Novo Nordisk remains optimistic about ongoing trials Artemis and Hermes as potential lifelines for their CKD program. Success could diversify their portfolio and introduce novel therapeutic options for CKD patients. Additionally, financial hurdles surfaced as Daiichi Sankyo saw an 11% share drop due to an accounting error, and Alnylam Pharmaceuticals' market value took a hit following a lowered revenue forecast for its TTR drug. On a global scale, the Trump administration has allocated $600 million to GAVI for childhood immunizations worldwide. This funding reversal emphasizes ongoing efforts to ensure vaccine accessibility across the globe—an essential component of public health initiatives. The dynamic nature of these developments reflects both the potential and challenges within the pharmaceutical landscape. The promising avenues presented by gene therapy, antibody-drug conjugates, and JAK inhibitors are tempered by clinical setbacks and financial volatility, underscoring the rigorous demands faced by industry stakeholders. In other industry news, AbbVie's Skyrizi continues to thrive despite increasing competition in the psoriasis market. With sales reaching $5.55 billion in Q2 2026, Skyrizi demonstrates the sustained demand for innovative biologics that enhance treatment efficacy and safety profiles. Karyopharm Therapeutics remains committed to its XPO1 inhibitor Xpovio despite setbacks in other indications like endometrial cancer. Their focus on myelofibrosis illustrates a strategic pivot towards hematologic malignancies where unmet needs persist. Oral GLP-1 receptor agonists are gaining ground as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie for dominance in weight management solutions. These oral formulations promise increased accessibility over traditional injectables. Regulatory arenas continue to evolve with AbbVie's Rinvoq gaining European clearance for alopecia and vitiligo. Such approvals highlight regulatory bodies' critical role in expanding market access across diverse therapeutic areas. Strategic partnerships also abound as WellSpan Health collaborates with Hippocratic AI to integrate artificial intelligence into healthcare solutions—a growing trend aimed at enhancing clinical decision-making capabilities. Meanwhile, Apnimed's $192 million IPO success indicates strong investor confidence in novel therapeutics like its sleep apnea treatment—a reflection of biopharma's financing dynamics where targeted therapies draw significant interest. Overall, these updates paint a vivid picture of an industry characterized by relentless innovation through scientific research, strategic alliances, and regulatory progress—all aimed at improving patient outcomes amidst evolving market demands. The industry's focus on breakthrough technologies continues to shape global health initiatives by offering new opportunities for patient care across various conditions. As companies navigate this dynamic environment marked by both promise and challenge—their ability to innovate scientifically while engaging strategically with regulators will be crucial to bringing novel therapies effectively into clinical practice where they can make meaningful impacts on patients' lives worldwide.Support the show

Nosipho Radebe is in conversation with Sean Coleman, CEO at South African Bookmakers’ Association (SABA)See omnystudio.com/listener for privacy information.

Alle Quellen finden Sie im Newsletter Zum Newsletter anmelden und Updates direkt am Montag morgen per Mail erhalten: https://bit.ly/newslettersustaind | Einfach auf "Subscribe" klicken Imprint: www.sustaind.de

Private equity is expanding into India’s K-12 school sector, following the same playbook it used to reshape private hospitals. Since Indian schools must legally operate as not-for-profit trusts, PE firms like KKR, Blackstone, and Kedaara invest indirectly through separate for-profit “OpCo” service companies that charge trusts for management, infrastructure, and operations—mirroring hospital structures. The appeal: predictable, long-term cash flow from families who rarely withdraw children mid-cycle, rising fees, and unmet demand for quality private education. Regulatory hurdles, fee caps, and mandated free seats for low-income students complicate profitability. Unlike hospitals, no major PE-backed education platform has yet achieved a successful exit, leaving the model’s long-term viability untested. Alenjith K Johny and Mohit Bhalla report; Anirban Chowdhury narrates for audio. You can follow Anirban Chowdhury on his social media: X and LinkedinCheck out other interesting episodes like:ET Deep Dive: Swipe Left on Reality,India wants manufacturing at 25% of GDP — will AI in factories help?, Tanay Kothari Wants To Kill The Keyboard, From Doer to Director: The LinkedIn Playbook for the AI Agea, Semaglutide Goes Generic: Big Pharma’s Moat Breaks and much more. Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.See omnystudio.com/listener for privacy information.

Speakers: Sean FitzGerald and Leanne Loranger    In this episode, Leanne and Sean revisit the rules for use of title and why those rules are important for physiotherapists, patients, and the public. The conversation explains who may use protected titles such as Physiotherapist, Physical Therapist, Physiotherapist Intern, and PT, and highlights why a physiotherapist's registration status matters—whether a registrant is entering practice, on leave, or retiring. They also discuss how physiotherapists should list academic credentials and additional training in a way that is accurate, transparent, and meaningful to patients. The episode reviews common questions about terms such as Clinical Specialist, acupuncturist, osteopath, doctor, clinical Pilates, and advanced practice, highlighting the importance of avoiding language that misleads or implies a credential or specialization the physiotherapist does not hold. Listeners are reminded to use their protected title, place it before other credentials, and explain their additional training clearly and transparently. Most of all physiotherapists are encouraged to be proud of the professional title they worked hard to earn. Resources ·       Titles, Credentials and Specialty Designations ·       Getting Titles Right Infographic

In this episode of The Med-Tech Talent Lab, Mitch Robbins sits down with Paul Arrandell, Chief Quality and Regulatory Officer at Jabil, to explore what it takes to build a quality organization that goes far beyond compliance.With more than 30 years of leadership experience across medical devices, diagnostics, aerospace, and automotive, Paul shares how quality leaders can become true strategic business partners by driving trust, improving business performance, and creating a culture that scales across complex global organizations. Drawing on his experience leading quality and regulatory across more than 90 sites worldwide, he discusses the challenges of standardizing quality systems, integrating acquired businesses, developing future leaders, and building a culture where accountability and continuous improvement become part of everyday operations.The conversation also explores why quality should be viewed as a competitive advantage instead of a cost center, how organizations can identify and develop high-potential talent, and where artificial intelligence has the potential to transform quality systems, regulatory intelligence, and operational decision making.Whether you're a Quality, Regulatory, Operations, or executive leader, this episode offers practical insights on building resilient organizations, developing strong teams, and positioning quality as a driver of business success.In this episode, you'll learn:• Why quality should be viewed as a strategic business function, not just a compliance requirement• How to build and sustain a quality culture across global manufacturing sites• The leadership principles behind developing high-performing teams and future leaders• Why trust is one of the most valuable outcomes of an effective quality organization• Common mistakes companies make when trying to standardize quality systems• How to use metrics and data to improve business performance instead of simply reporting compliance• Where AI can help quality organizations become more proactive, efficient, and data-driven• Why experienced professionals will remain essential even as AI transforms the future of quality...and so much more!Paul Arrandell on LinkedIn:https://www.linkedin.com/in/paul-arrendell/Jabil on the web:www.jabil.com

This week, I had the pleasure of speaking with Dr. Susanna W. Blair, Senior Director of Regulatory and Technical Affairs for the Consumer Brands Association (CBA), which represents the interests of the consumer-packaged goods (CPG) community. Having left the U.S. Environmental Protection Agency (EPA) after a distinguished career as a senior scientist and policy expert, Dr. Blair is putting her science policy chops to good use at CBA. We discuss CBA's mission, its focus on food and beverage ingredients, how Make America Healthy Again (MAHA) advocacy has impacted CBA, the Association's focus on the Generally Recognized as Safe (GRAS) framework, among other priority projects CBA is pursuing, and much more. ALL MATERIALS IN THIS PODCAST ARE PROVIDED SOLELY FOR INFORMATIONAL  AND ENTERTAINMENT PURPOSES. THE MATERIALS ARE NOT INTENDED TO CONSTITUTE LEGAL ADVICE OR THE PROVISION OF LEGAL SERVICES. ALL LEGAL QUESTIONS SHOULD BE ANSWERED DIRECTLY BY A LICENSED ATTORNEY PRACTICING IN THE APPLICABLE AREA OF LAW. ©2026 Bergeson & Campbell, P.C.  All Rights Reserved

Dr. Katherine Hockman, Director of the Division of Hospital Medicine at NYU Langone Health, and Dilshad Marolia, System Director of Hospitals and Regulatory and Policy Management at NYU Langone Health, are co-leaders of the Patient Experience Book Club for the hospital employees.  Operating since 2012, the program has grown from six books to 12 books per year, with sessions offered in-person and virtually to reach across the entire health system and, in addition, hosts pop-up sessions with visiting authors. The club helps break down departmental silos within the hospital, fostering connections among employees by creating a safe space for intellectual and emotional engagement while helping to combat workplace burnout. Katherine explains, "So my feeling is the Patient Experience Book Club is so much more than just a club where we read books and talk about them. It's really become a community of individuals who get together and share their experience in caring for some of our sickest patients. And it's also become a great venue for the faculty and staff to get to know each other a lot better and to share some of their vulnerabilities. And Dilshad and I, we've really taken it in many, many different directions. So we started off just reading six books a year, and now we're doing 12 books a year and two sessions a month, one in person and one on video for people who are in all parts of our system who can't make it in person."   Dilshad elaborates, "But now also as a community of 53,000 people in our own health system and part of the wider community of New York City and New York State even, how do we view our communities and ourselves, and what books are transforming us, and what are we taking away from each experience? And the level of intellectual engagement is one thing, but there's a high, high level of emotional engagement that I think is rare to find in the workplace to create these safe spaces where you have a vehicle, and I'll use that word, through which you can have a discussion about a very pointed topic beyond, say, an academic journal." #NYULangone #Bookclub #PatientExperience #HumanityinHealthcare #HealthcareLeadership #EmpathyInHealthcare #BurnoutPrevention #HospitalCulture #MedicalHumanities nyulangonehealth.org Download the transcript here

Dr. Katherine Hockman, Director of the Division of Hospital Medicine at NYU Langone Health, and Dilshad Marolia, System Director of Hospitals and Regulatory and Policy Management at NYU Langone Health, are co-leaders of the Patient Experience Book Club for the hospital employees.  Operating since 2012, the program has grown from six books to 12 books per year, with sessions offered in-person and virtually to reach across the entire health system and, in addition, hosts pop-up sessions with visiting authors. The club helps break down departmental silos within the hospital, fostering connections among employees by creating a safe space for intellectual and emotional engagement while helping to combat workplace burnout. Katherine explains, "So my feeling is the Patient Experience Book Club is so much more than just a club where we read books and talk about them. It's really become a community of individuals who get together and share their experience in caring for some of our sickest patients. And it's also become a great venue for the faculty and staff to get to know each other a lot better and to share some of their vulnerabilities. And Dilshad and I, we've really taken it in many, many different directions. So we started off just reading six books a year, and now we're doing 12 books a year and two sessions a month, one in person and one on video for people who are in all parts of our system who can't make it in person."   Dilshad elaborates, "But now also as a community of 53,000 people in our own health system and part of the wider community of New York City and New York State even, how do we view our communities and ourselves, and what books are transforming us, and what are we taking away from each experience? And the level of intellectual engagement is one thing, but there's a high, high level of emotional engagement that I think is rare to find in the workplace to create these safe spaces where you have a vehicle, and I'll use that word, through which you can have a discussion about a very pointed topic beyond, say, an academic journal." #NYULangone #Bookclub #PatientExperience #HumanityinHealthcare #HealthcareLeadership #EmpathyInHealthcare #BurnoutPrevention #HospitalCulture #MedicalHumanities  nyulangonehealth.org Listen to the podcast here

This Week In Startups is made possible by: Northwest Registered Agent- NorthwestRegisteredAgent.com/twist Odoo - Odoo.com/twist MongoDB - MongoDB.com/ai   Today's show: The FCC's decision to ban Chinese humanoid robots over security concerns is a boon to American startups, which now face a narrower competitive market. But where should we draw the line on security over competition? Menlo Ventures' Deedy Das, Weisburd Pierce's David Weisburd, Plexo Capital's Lo Toney, and LAUNCH's Jason Calcanis broke down how they differentiate between legitimate security concerns and purported regulatory capture. Today's venture capital roundtable also dug into OpenRouter's possible sale to Stripe, changing tokenomics, the Indian market for startups, and even DoorDash's drone-delivery business taking flight. Guest Links: Deedy Das https://x.com/deedydas Menloe Ventures https://menlovc.com/ Lo Toney https://x.com/lo_toney Plexo Capital https://www.plexocap.com/ David Weisburd https://x.com/DWeisburd Weisburd Pierce https://www.weisburdpierce.com/ Jason Calcanis https://x.com/Jason LAUNCH https://launch.co/ Show Links: The FCC's decision regarding Chinese robots https://www.fcc.gov/document/fcc-adds-foreign-produced-power-inverters-and-robots-covered-list-0 Pacing the Frontier letter https://www.pacingthefrontier.com/ Cursor Start https://cursor.com/blog/cursor-start-india Stripe may buy OpenRouter https://www.axios.com/2026/07/24/stripe-openrouter-merger-ai-currency OpenRouter financials https://www.theinformation.com/articles/openrouter-financials-suggest-steep-price-possible-acquirer-stripe?rc=g3wfdp Kimi K3 license https://huggingface.co/moonshotai/Kimi-K3/blob/main/LICENSE Pangram https://www.pangram.com/ Tau Robotics https://www.tau-robotics.com/ Zipline https://www.zipline.com/ Manna https://www.manna.aero/ Kindred Ventures https://kindredventures.com/ Autolane https://goautolane.com/ Salmon Labs https://salmonrun.ai/   Timestamps: 0:00 The FCC bans Chinese humanoid robots 2:18 Waymo, Uber, Robotaxi, and the global BYD threat 10:30 MongoDB - AI-assisted and agentic coding is helping you build faster than ever. Start building at https://MongoDB.com/ai 15:45 The "Pacing The Frontier" letter (1,100+ AI staffers warn on RSI) 19:51 Odoo - The all-in-one business platform. Get started for free at https://Odoo.com/twist 21:07 Regulatory capture vs. genuine concern 30:09 Northwest Registered Agent - Get more when you start your business with Northwest. In 10 clicks and 10 minutes, you can form your company and walk away with a real business identity — Learn more at https://northwestregisteredagent.com/twist 37:57 Have we reached AGI? 38:35 Stripe eyes OpenRouter at $10B 39:19 Does OpenRouter have a moat? 47:13 Kimi K3's license and neocloud margins 49:34 Claude Tag and the future of AI-mediated workplaces 53:26 Cursor Start, ChatGPT Go, and the India market 1:02:03 Have we solved AI detection? 1:11:20 Tau Robotics $30/hour robotic housecleaning 1:12:49 Job loss, and the social safety net 1:18:25 DoorDash Air takes on Zipline, Manna 1:21:00 Portfolio shout-outs Subscribe to the TWiST500 newsletter: https://ticker.thisweekinstartups.com Check out the TWIST500: https://www.twist500.com Subscribe to This Week in Startups on Apple: https://rb.gy/v19fcp   Follow Lon: X: https://x.com/lons   Follow Alex: X: https://x.com/alex LinkedIn: ⁠https://www.linkedin.com/in/alexwilhelm   Follow Jason: X: https://twitter.com/Jason LinkedIn: https://www.linkedin.com/in/jasoncalacanis   Great TWIST interviews: Will Guidara, Eoghan McCabe, Steve Huffman, Brian Chesky, Bob Moesta, Aaron Levie, Sophia Amoruso, Reid Hoffman, Frank Slootman, Billy McFarland   Check out Jason's suite of newsletters: https://substack.com/@calacanis   Follow TWiST: Twitter: https://twitter.com/TWiStartups YouTube: https://www.youtube.com/thisweekin Instagram: https://www.instagram.com/thisweekinstartups TikTok: https://www.tiktok.com/@thisweekinstartups Substack: https://twistartups.substack.com

Matty A. and Ryan Breedwell dive into a packed week for the financial markets, starting with predictions for the upcoming FOMC rate decision and the impact of the ongoing Iran conflict on global oil prices. They explore how inflation and geopolitical tensions are keeping the S&P 500 range-bound, while highlighting crucial earnings reports from major AI and semiconductor companies like SanDisk, Seagate, and Nvidia.The hosts also analyze the recent spike in United States real estate foreclosures, breaking down why record-high homeowner equity and supply shortages mean a housing crash is highly unlikely. Finally, the conversation shifts to digital assets, discussing the Crypto Clarity Act, the regulatory threat to meme coins, and how tokenization could soon reshape institutional finance.KEY TOPICS DISCUSSEDFOMC rate hike probabilities and Citadel's surprise hike prediction.Impact of the Iran conflict on global oil prices and WTI trends.Semiconductor stock pullbacks and AI data storage investments.Q2 tech earnings expectations for Meta, Apple, and Microsoft.Analysis of rising United States real estate foreclosures compared to 2019.Record homeowner equity and the national housing supply shortage.The Crypto Clarity Act and the future of real world asset tokenization.Regulatory crackdowns on meme coin markets and platforms like PumpFun.KEY TAKEAWAYSA surprise FOMC rate hike is highly unlikely given current market conditions, despite some hawkish institutional forecasts.Geopolitical energy shocks are being digested faster by the market, with oil prices retreating sharply after recent spikes.Semiconductor and memory storage companies present strong buy opportunities as they continue to beat earnings despite broader tech sector pullbacks.The current real estate market is insulated from a crash due to a massive 11 trillion dollars in tappable equity and pervasive sub-6 percent mortgage rates.The impending Crypto Clarity Act will likely eliminate unregulated meme coin exchanges while attracting trillions in institutional capital to legitimate tokenization projects.CONNECT & TAKE ACTIONImagos Income Fund: Text "INCOME" or "DEALS" to 844-447-1555 to learn more about Matty A's private debt fund targeting 10% fixed returns paid out monthly.

Does next generation geothermal have the capital and regulatory certainty to scale? In part two of this two-part series, host Sebastian Duque Rios continues the conversation on geothermal energy, turning to the financing and policy side of the equation with a panel of experts: Caroline de Bossart (Grantham Foundation), Drew Nelson (Project InnerSpace), and Susannah Dibble (Environmental Law Institute). The conversation first digs into the challenges of financing geothermal energy. The panel unpacks the unique risk profile of geothermal projects (front-loaded drilling costs, resource uncertainty, and the absence of standardized data) and how emerging tools could unlock institutional lending and insurance the way similar frameworks have for oil and gas. They also explore the regulatory patchwork shaping geothermal's growth state by state, from Texas and Colorado's bipartisan legislative wins to the Mountain West Coalition's push for coordinated permitting and financing reform, and what an ideal legal and regulatory environment — one built to keep pace with fast-moving technology — could look like. Along the way, the panel covers permitting timelines, water rights and reinjection issues, and where organizations like ELI can help close the remaining research and policy gaps. It's a wide-ranging look at what stands between geothermal and the capital it needs to scale, and the policy moves that could unlock it.For more information, see part one of this two-part series and ELI's webinars on The Future of Geothermal:Power GenerationHeating and Cooling of BuildingsFinancing geothermal: why capital is lagging behind (3:48)Building a regulatory environment that unlocks investment (14:01)State-by-state: geothermal's regulatory patchwork (18:59)Water law as a case study (30:58)Concluding thoughts & what to watch for as geothermal scales (35:19) ★ Support this podcast ★

Antares just closed a massive $470M Series C, was welcomed to the Oval Office by President Trump to celebrate becoming the first startup to achieve reactor criticality under the Department of Energy's reactor pilot program, and is now racing toward delivering the first commercial microreactors to the U.S. military. Just three years after being founded, the company expects to surpass $1B in defense contracts while attempting to restart America's nuclear industrial base. CEO Jordan Bramble joins Valley of Depth to unpack what it actually took to build and operate a nuclear reactor in under a year, why Antares believes the military (not hyperscale data centers) is the fastest path to commercial nuclear power, and how microreactors could fundamentally reshape everything from missile defense and remote military installations to space exploration. We also cover: Why achieving reactor criticality is a historic milestone for American nuclear energy How Antares compressed decades of nuclear development into a startup timeline Why the company chose defense as its beachhead market instead of AI data centers The manufacturing, regulatory, and supply chain strategy behind scaling microreactors How nuclear power could enable Golden Dome, space infrastructure, and the next era of national security • Chapters • 00:00 - Trailer 00:54 – Jordan at the White House 02:57 – What does criticality mean? 04:29 – How hard is reaching criticality? 08:48 – What $600M in fundraising will allow Antares to do 09:58 – How did Antares get to criticality first? 12:55 – How the government's approach to nuclear has changed since Jordan's time at the Office of Management & Budget 15:25 – How small modular reactors fit in the nuclear tech landscape 19:02 – Space-based civilian use cases for nuclear 20:57 – Antares's approach to fuel availability and supply chains 25:56 – Electricity in 2027 27:14 – Regulatory hurdles 30:12 – The production line Antares is building 31:33 – The road to 30 reactors a month 33:22 – The data center component 37:22 – Is it just a coincidence that 4 companies reached criticality by the July 4th deadline? 39:48 – How would an investor know if a nuclear company is on the right path? 43:09 – What would Jordan have done differently with Antares? 44:36 – What will Jordan be most proud of about Antares when he's 80?   • Show notes • Antares' website — https://antaresindustries.com/ Jordan's socials — https://x.com/jordanbramble Mo's socials — https://x.com/itsmoislam Payload's socials — https://x.com/payloadspace /  https://www.linkedin.com/company/payloadspace Ignition's socials — https://x.com/ignitionnuclear / https://www.linkedin.com/company/ignition-nuclear/ Tectonic's socials  — https://x.com/tectonicdefense / https://www.linkedin.com/company/tectonicdefense/ Valley of Depth archive — Listen: https://pod.payloadspace.com/   • About us • Valley of Depth is a podcast about the technologies that matter — and the people building them.  Brought to you by Arkaea Media, the team behind Payload (space), Ignition (nuclear energy), Decoding Bio (biotech) and Tectonic (defense tech), this show goes beyond headlines and hype. We talk to founders, investors, government officials, and military leaders shaping the future of national security and deep tech. From breakthrough science to strategic policy, we dive into the high-stakes decisions behind the world's hardest technologies. Payload: www.payloadspace.com Tectonic: www.tectonicdefense.com Ignition: www.ignition-news.com Decoding Bio: www.decodingbio.com

In this month's episode, Anu Pandya is joined by Mariela Isern, member of the IASB technical staff, and Deanna Louth, PwC partner, to discuss a new IFRS Accounting Standard – IFRS 20 Regulatory Assets and Regulatory Liabilities.Find out more at PwC's IFRS Talks homepage.

In this episode, I had the chance to speak with Wael ElSahhar, cofounder and CEO at MidLyr, and Kirsten Muetzel, founding principal & CPA at KLM Advisory. We discussed:* The role of AI in compliance in a rapidly changing regulatory environment* The differences in how fintechs, technology service providers, banks think about risk* Key lessons from what the industry has seen unfold in banking as a service over the last several years* How firms are actually using AI in compliance – and what risks AI itself may pose* And more!A reminder, if you're enjoying this show, please follow, rate & review on your preferred podcast platform, as it really helps others to find the show.And if you want to help support Fintech Business Weekly and independent journalism, upgrade to a paid subscription or reach more than 93,000+ listeners by sponsoring an episode. Get full access to Fintech Business Weekly at fintechbusinessweekly.substack.com/subscribe

Digestion is regulated by a complex network of hormones, peptides, and neural signals. In this episode, we review the major gastrointestinal hormones, introduce several secondary regulatory peptides, and explain how the GI tract senses its luminal contents and integrates multiple signals to control digestive function. After listening to this episode, you should be able to: Identify the source, release stimulus, and function of the major gastrointestinal hormones, including secretin, cholecystokinin (CCK), gastrin, and vasoactive intestinal peptide (VIP). Summarize the release stimuli and functions of key GI regulatory peptides, including bombesin, GLP-1, GLP-2, ghrelin, leptin, motilin, somatostatin, and glucose-dependent insulinotropic polypeptide (GIP). Explain how the physical and chemical properties of luminal contents are sensed and how they trigger hormonal responses. Describe how GI cells integrate hormonal and neural inputs to regulate digestive function. You can also check out the original brick on Gastrointestinal Regulatory Substances from our Gastrointestinal collection, which is available for free. Explore more with USMLE-Rx Create a free USMLE-Rx account at www.usmle-rx.com. You'll receive five days of full access to Rx360+, including over 800 Rx Bricks. After the trial, you can continue accessing more than 150 free Bricks, including the complete General Microbiology and Cellular and Molecular Biology collections. Enjoyed the episode? Please consider leaving us a review on Apple Podcasts. Reviews help more medical students and future medical students discover the podcast…and help us continue creating resources for the physicians of tomorrow.

Connect with Early Riders — https://www.earlyriders.com/contactConnect with Onramp — https://onrampbitcoin.com/contact-us/Presented collaboratively by Early Riders & Onramp Media…Final Settlement is a weekly podcast covering capital markets, dealmaking, early-stage venture, bitcoin applications and protocol development.This week Michael, Liam, and Brian open on the open-versus-closed AI debate: Jensen Huang's first-ever tweet and NVIDIA's letter backing open models, the new Security Alliance consortium, the researchers quietly wishing they could slow it all down, and NVIDIA's reported $250 billion financing for OpenAI's Ohio data center. They dig into Jack Dorsey's Buzz, the open-source workspace built on the same Noster and Bitcoin primitives as BitChat, and what shared compute and censorship-resistant protocols mean as BitChat downloads spike 32-fold in India. The guys run through a stack of payments deals: Stripe's talks to buy OpenRouter near $10 billion, Cursor, Ramp, and Meta building model routers, and Natural Pay's $30 million Series A for agentic payments. They get into their favorite topic, the DATs: Mallers exiting 21 Capital as Tether's XXI merger collapses, Strategy's first Stretch buyback, and the new Bitcoin security consortium taking on quantum. They close on Augustus's $180 million raise, Worldcoin, and Travis Kalanick's return with Adam.Chapters00:00 - Introduction and overview of AI and open models02:10 - Jensen Huang's first tweet on open models and global cooperation09:08 - Discussion on slowing AI development and game theory18:03 - Jack Dorsey's Buzz: Open source workspace and primitives24:55 - Shared compute, decentralized protocols, and open standards35:02 - Regulatory landscape and geopolitical implications45:11 - Impacts on privacy, security, and censorship resistance54:03 - Recent deals and industry movements in AI and crypto01:02:08 - The future of Bitcoin, open protocols, and decentralized dataIf you found this valuable, please subscribe to Early Riders Insights for access to the best content in the ecosystem weekly: https://www.earlyriders.com/researchKeep up with Michael:https://x.com/MTangumaKeep up with Liam:https://x.com/Lnelson_21Keep up with Brian:https://x.com/BackslashBTC

Tuesday, July 28 marks the 700th live edition of the commemorative Talk Ten Tuesdays broadcast. And in honor of this celebration, the ICD10monitor producers of the popular news and information service have invited Dennis Jones, the assistant vice president of revenue cycle for Jefferson Health, to be the guest host.During the first half of the broadcast, our other well-known subject-matter experts will also join the broadcast with more news to report, including the following:• Tech Report: Senior healthcare analyst Frank Cohen to reveal how when claims are viewed in isolation, there is a great likelihood of audits.• POV: Penny Jefferson, cohost of Talk Ten Tuesdays, will share her point of view (POV) during the broadcast.• The Coding Report: Chris Geiger, will report on the latest coding news.• CDI Report: Cheryl Ericson will provide an update on clinical documentation integrity (CDI).• SDoH Report: Tiffany Ferguson, the CEO for Phoenix Medical Management, will report on news that's happening at the intersection of patient care and medical record coding.Then, during the second half of the broadcast, we have invited a host of renowned guest panelists, including the following:1. Edward Roche2. Ronald Hirsch, MD3. Matthew Albright4. Maureen Testoni. Esq.5. Denise Buenning6. Fred Stodolak

An AI agent slipped its sandbox and hacked a real company for days before anyone noticed and that single incident reframes everything else this week. Paul Roetzer and Mike Kaput connect it to Kimi K3's arrival at the frontier, the "Open Weights and American AI Leadership" letter, and the regulation fight taking shape in Washington. They break down open weight vs. open source in plain terms, explain why Anthropic is standing alone, and run rapid fire on Alphabet's Q2, the data center backlash, the jobs debate, and Claude Opus 5. AI-Pulse Survey: Fill out this week's AI-Pulse Survey here. Show Notes: Access the show notes and show links here Timestamps: 00:00:00 — Intro 00:07:31 — OpenAI Models Escape and Hack Hugging Face 00:27:49 — Kimi K3 and China's Open-Source Surge 00:50:52 — Open Weights and American AI Leadership 01:07:23 — Demis Calls for a Frontier AI Standards Body 01:12:17 — Google's AI-Fueled Q2 01:15:22 — White House Redirects Research Billions Toward AI 01:17:42 — The Data Center Backlash Goes National 01:21:17 — Why Hasn't AI Increased Unemployment? 01:27:15 — Which AI Tools Should You Use? 01:32:06 — AI Use Case Spotlight 01:36:01 — AI Product and Funding Updates This week's episode is brought to you by MAICON, our 6th annual Marketing AI Conference, happening in Cleveland, Oct. 13-15. The code POD100 saves $100 on all pass types. For more information on MAICON and to register for this year's conference, visit www.MAICON.ai. Visit our website Receive our weekly newsletter Join our community: Slack Community LinkedIn Twitter Instagram Facebook YouTube Looking for content and resources? Register for a free webinar Come to our next Marketing AI Conference Enroll in our AI Academy 

Marty and John dig into the Houthis blocking the Bab el Mandeb strait, oil whipsawing on peace headlines, and why Lloyd's of London pulling war coverage matters for US insurers. They get into Trump's air defense stockpile problem, Chinese diesel demand falling off a cliff, and why the MOVE index staying subdued even as yields rise is the chart to watch. The bulk of the show is an extended breakdown of the open versus closed AI model debate, why the Hugging Face hack exposes the absurdity of current guardrails, and how the real axis of conflict is US versus China, not open source versus safety. They close with Bitcoin long term holder supply hitting 84 percent, a classic bottoming signal.

In this episode of Medsider Radio, we sat down with Vijit Sabnis, co-founder and CEO of Adaptyx Biosciences.Adaptyx is a Stanford spinout developing wearable technology for continuous molecular monitoring.Over the past 20 years, Vijit has worked at the intersection of deep technology as an inventor, founder, and investor. Before Adaptyx, he was a Partner at Khosla Ventures and co-founded Solar Junction to commercialize high-efficiency solar cell technology. He holds a Ph.D. in Electrical Engineering from Stanford.In this interview, Vijit discusses how to recognize when a scientific idea is worth building a company around, how to build startup-style learning cycles when spinning technology out of academia, and designing products that are easy for clinicians and consumers to adopt. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Vijit Sabnis, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:17) - Vijit's path from Stanford, solar energy, and venture capital to building Adaptyx (07:25) - How Adaptyx is trying to do for hormones what continuous glucose monitors did for diabetes (13:50) - The signals Vijit looked for before founding Adaptyx (25:35) - How Adaptyx turned academic research into startup-speed learning cycles (32:15) - Why cortisol became the company's first clinical application (36:26) - How Adaptyx is designing new molecular data to fit existing clinical workflows (42:12) - Why new consumer health platforms opened new paths to commercialization (47:24) - Fundraising in an era of shorter attention spans

Preventing DAO Governance Attacks + Building a Music DAO and AI Agent Legal Entities (with Zaal / Better Call Zaal)Adam Miller hosts Just DAO It and interviews Zaal (“Better Call Zaal”), founder of the ZAO, an on-chain music community incubator aiming to return profit-margin data and IP rights to independent artists. They discuss BonqDAO's low-turnout governance “apathy attack” and mitigations like security councils, timelocks, and ZAO's illiquid, soulbound “respect” governance tokens with extended voting/veto periods. The episode covers ENS's newly adopted security council, Cardano and Solana governance updates, MetaDAO's ownership coins and futarchy, Lido's restructuring, and Arbitrum revenue sharing. Regulatory news includes the U.S. CLARITY Act ethics dispute and SEC safe-harbor proposals. In AI agent news, Adam critiques early agent hype and highlights emerging legal structures (Marshall Islands, Delaware draft, Bermuda). Zaal explains ZAO's reputation-based governance, Wave Wars live-traded music battles that pay artists, upcoming ZAOstock in Maine, and plans for a community-weighted AI agent (“XOL/Zol Bot”) to manage funds via a legal entity.00:00 Welcome and Introductions01:11 BonqDAO Governance Attack03:11 ZAO Defense Mechanisms04:43 ENS Security Council Update07:10 Governance Rapid Fire11:58 Regulatory CLARITY Act14:17 AI Agent News and Reality Check19:03 Break and MIDAO Guide19:47 Zaal Origin Story21:21 Why Blockchain Matters23:43 Inside the ZAO Respect System25:32 Reputation Voting Challenges30:10 Progress and Community Metrics31:46 Wave Wars Explained35:24 ZAO Festivals and ZAOstock37:06 AI Agent Legal Entity Plans40:01 Where to Find Zaal and Wrap UpContact / Links:Zaal (Farcaster): zaalZaal (X): @bettercallzaalZaal (Email): info@thezao.comWave Wars: https://wavewarz.comAdam (X): @0xthrillerAdam (Farcaster): The ThrillerMIDAO (X): @MIDAODSMIDAO: https://midao.orgAI Agent incorporation guide: https://midao.org/guides

Maybe it's the summer doldrums that keep otherwise rational people from taking a chance—especially when better alternatives may be available. But according to physician and attorney Dr. John K. Hall, the special guest on the next live edition of Monitor Mondays, some individuals prefer to maintain the status quo rather than pursue a potentially better approach. Case in point: Aetna's recent discharge policy. Beyond the policy itself, which seems to be causing consternation among some hospitals, are there other examples? Listen to the special broadcast Monday, July 27, at 10:00 a.m. EST.The broadcast will also include these instantly recognizable segments:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Adam Brenman, legislative affairs liaison for Zelis, will report on current healthcare legislation.

The Trump administration has released its latest Unified Agenda, offering the clearest picture yet of what federal agencies expect to work on in the coming months. While the White House continues to emphasize deregulation, the agenda shows a government that remains deeply engaged in writing and revising rules. Joining me for a closer look, Will Yeatman, the new director of the Regulatory Studies Center at George Washington University.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome back to a special encore presentation of Turn on the Lights! As we continue our transition series, our new host, Dr. Philip, has selected one of our most impactful and widely listened-to conversations from the archives to revisit. He introduces this timely discussion with Chris Van Gorder, which explores how cost shifting, regulatory mandates, and Medicare Advantage risk transfer are pushing healthcare toward structural unaffordability. Summary: Leading a major health system today means juggling patient-first ethics with a financing model that keeps tightening the screws. In this episode, Chris Van Gorder, President and Chief Executive Officer of Scripps Health, explains why health care is becoming structurally unaffordable amid soaring premiums, uncompensated emergency care, and rising input costs. He describes how hospitals have become the default safety net as county systems disappear, while underpayment by Medicare and Medicaid forces cost shifting onto employers and commercially insured patients. Van Gorder also highlights California's seismic rebuilding mandates, which create massive capital pressure without matching reimbursement. He critiques managed care, value-based care, and Medicare Advantage for pushing risk onto providers through prior authorization and denials, recounting Scripps' difficult decision to exit several Medicare Advantage contracts after heavy losses and the downstream impact on patients. Tune in and learn how payment design, intermediaries, and regulation shape what hospitals can sustain and what patients can access. About Chris Van Gorder: Chris Van Gorder, MPA, FACHE, is the President and Chief Executive Officer of Scripps Health in San Diego, where he has led the organization since 2000 after serving as its Chief of Healthcare Operations and COO. A veteran healthcare executive with decades of experience across California hospital systems, he previously held CEO and senior leadership roles at Long Beach Memorial Medical Center, Anaheim Memorial Medical Center, and Little Company of Mary Hospital. Beyond health system leadership, he has served on multiple boards, including Prolacta Bioscience and previously Abiomed and Z-Medica, and he has been active in national and civic service as a commissioner for the U.S. National Commission for UNESCO. He also brings an uncommon public-safety background, including reserve service with the San Diego Sheriff's Department and long-running involvement with California's Emergency Medical Services Authority, earning a Distinguished Service Medal. An educator and author, he teaches at USC and wrote The Front-Line Leader (2014). Things You'll Learn: Healthcare executives are dealing with an unprecedented volume of simultaneous operational, financial, and workforce demands, raising the stakes of everyday decisions.  Affordability isn't just a household problem; it's a system design problem that forces hospitals to cover the growing cost of unpaid care.  Cost shifting is not a theory; it is the mechanism that pushes public underpayment onto commercial premiums.  Regulatory and capital mandates can dramatically raise costs without generating new revenue, especially in California.  Medicare Advantage often adds friction through narrow networks, prior authorization, and payment disputes, while shifting risk downhill. Walking away from bad contracts can stabilize a system financially, but it creates real disruption for patients and exposes policy gaps in switching coverage. Resources: Connect with and follow Chris Van Gorder on LinkedIn. Follow Scripps Health on LinkedIn and explore their website! Learn more about your ad choices. Visit megaphone.fm/adchoices

For episode 756 of the BlockHash Podcast, host Brandon Zemp is joined by Lex Karushin, Partnerships Manager for Finchtrade.Lex has over five years of experience in the crypto space, with most of his career spent in Web3 startups, helping teams scale through new business development, strategic partnerships, and capital raising. His background spans DeFi, NFTs, and token launches, and with a foundation in management and finance.

Many medical device startups assume they're audit ready because they have documented procedures, completed templates, and a Quality Management System in place.However, successful audits require much more than organized documentation.In this episode of the Medical Device Made Easy Podcast, we welcome Chiratana Pot from Enlil to discuss what true audit readiness looks like and why continuous compliance is far more effective than preparing only when an audit is scheduled.What You'll LearnWhat Is an Audit Really?Many organizations view audits as exercises designed to uncover mistakes.In reality, audits evaluate whether your Quality Management System is implemented effectively and consistently—not simply whether procedures exist.Compliance vs. Audit ReadinessBeing compliant and being audit ready are not always the same.The discussion explores how companies can move beyond documentation and demonstrate that their processes are actively followed throughout the organization.Common Startup MistakesDrawing from experience working with MedTech startups, Chiratana shares the most frequent challenges organizations encounter before their first audit, including assumptions that often lead to unexpected findings.Why Traceability MattersOne of the central themes of the episode is traceability.We examine how effective traceability connects requirements, risks, design decisions, verification activities, and documentation—making change management more efficient and strengthening overall compliance.How Enlil Supports Connected DevelopmentThe conversation concludes with an overview of Enlil's approach to connected development, explaining why integrating quality into product development from the beginning helps organizations maintain continuous audit readiness rather than relying on last-minute preparation.Key TakeawayAudit readiness is not a checklist completed before an inspection.It's the result of building a culture where quality, traceability, and compliance are embedded into everyday work.For MedTech startups, developing this mindset early can simplify audits, improve product quality, and create a stronger foundation for long-term regulatory success.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.Who is Chiratana (CP) Pot? Chiratana (CP) Pot is Senior Director of Product at Enlil, a cloud-native, AI-driven development traceability platform built for medical device and life sciences organizations. Enlil connects quality, regulatory, R&D, manufacturing, and operations teams through a unified system of record, enabling traceability, auditability, and regulatory readiness across the product lifecycle. CP works with MedTech organizations to strengthen design controls and audit readiness. He is a frequent contributor on topics including design controls, lifecycle traceability, and regulatory readiness, helping organizations move beyond documentation compliance to evidence-based product development.LinkChiratana's linkedin: https://www.linkedin.com/in/chiratana-pot/Website: https://enlil.com/Enlil's LinkedIn: https://www.linkedin.com/company/enlil-inc/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

In this episode, HR thought leader Tim Sackett joins host David Turetsky to explore the current landscape of artificial intelligence in HR, talent acquisition, and broader workforce management. They discuss the gap between technological potential and real-world application, legal and ethical challenges, and how government regulation could shape the future of AI in HR.  In this episode:  The real vs. perceived capabilities of AI in HR based on recent conferences and practitioner understanding  The legal issues emerging from AI use in recruiting, including Fair Credit Reporting Act concerns and litigation risks  The influence of government and regulatory bodies, with insights into new appointments like Keith Sondralin at the Department of Labor  The analogy of AI's growth and adoption to consumer products, highlighting how HR leaders can start integrating AI effectively  The untapped potential of blockchain for employee data integrity and verification in the future workforce  Practical advice on how HR practitioners can educate themselves quickly on AI basics to avoid vendor confusion  The importance of embedding AI into business and HR strategy to genuinely solve problems rather than just automate tasks  The ethical and security concerns linked to identity fraud, insider threats, and malicious use of AI for employment fraud  Timestamps:   00:00 - Welcome and episode overview on AI's impact in HR 00:48 - Insights into Tim's recent conference experiences and the state of AI learning among HR professionals 02:35 - The hype versus the real application of AI in talent acquisition 02:57 - Fun facts about Tim Sackett: a Belieber and a Swiftie 03:48 - The quality and impact of recent Super Bowl performances and music preferences 05:02 - Discussing the upcoming Rush tour anniversary and nostalgia for classic rock 06:34 - The intersection of AI and HR conference trends, gap analysis between practitioners and tech providers 07:50 - The knowledge gap in HR regarding AI capabilities and the risk of vaporware marketing 09:01 - Foundations of HR's misunderstanding of existing HR tech systems and AI's rapid evolution 11:33 - Legal challenges with AI, including Wells Fargo and Workday litigations, and compliance risks 13:07 - The potential for AI to cause or prevent legal liabilities and litigation 15:00 - New leadership at the Department of Labor and its implications for AI regulation 17:10 - Political influences on regulatory approaches and the need for national AI legislation 19:54 - Blockchain's dormant potential for workforce data sovereignty and validation 22:07 - The future of digital identity verification and the use of blockchain for employee records 24:11 - Risks of identity fraud and the importance of robust verification methods 26:22 - How AI can both combat and exacerbate identity fraud and security vulnerabilities 28:25 - Insider threats, employment fraud, and the importance of vigilance in digital security 31:10 - Strategies for HR leaders to become AI literate with minimal time investment 33:24 - The importance of understanding what "agent" and "automation" truly mean in HR tech markets 35:23 - Aligning AI initiatives with business and HR strategies to solve real problems 37:07 - Cost considerations, the hidden expenses of AI, and the importance of planning for ROI 38:48 - The "free" AI myth and the real costs of tokens, processing, and hardware investments 40:08 - The impact of AI data quality on recommendations and organizational decision-making 41:04 - Closing remarks and appreciation for Tim Sackett's insights    Resources & Links:  Anthropic's Prompt Engineering Video  Keith Sondralin - Department of Labor  Claude AI by Anthropic  ChatGPT by OpenAI  Gemini AI by Google  The Fair Credit Reporting Act  Connect with Tim Sackett:  LinkedIn  Twitter  Note:   For HR leaders, gaining a foundational knowledge of AI is critical. Resources like Anthropic's short videos or AI primer courses can accelerate understanding and help avoid vendor hype and legal pitfalls. 

In this special crossover episode of Inside Employment and Inside Safety, Steve Bell, Tony Wood and Lucy Boyd explore the increasingly complex regulatory landscape facing Australian employers and the growing scrutiny from workplace, safety and human rights regulators. Steve, Tony and Lucy discuss the rise in regulatory investigations and enforcement activity, the challenges employers face when responding to overlapping regulators, and the Australian Human Rights Commission's evolving approach to enforcing the positive duty to prevent sexual harassment. They also share practical insights on governance, compliance and how organisations can prepare for greater regulatory scrutiny.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of significant breakthroughs and strategic moves reshaping the industry landscape. Repligen Corporation's recent decision to acquire BioLife Solutions for $1.5 billion marks a pivotal moment in the cell therapy sector. BioLife Solutions' expertise in cryopreservation media is integral to maintaining cell viability during storage and transport—an essential factor for the success of cell therapies in oncology and regenerative medicine. This acquisition ensures Repligen a stable supply chain to support the burgeoning demand for advanced therapeutic options, potentially enhancing patient outcomes through more reliable treatments. Meanwhile, Novartis is expanding its reach in South Korea with a $95 million investment aimed at enhancing its radioligand therapy supply chain. Radioligand therapy represents a groundbreaking approach in oncology, utilizing targeted radioactive particles to specifically attack cancer cells while sparing healthy tissue. This strategic investment underscores Novartis's commitment to ensuring a robust infrastructure for delivering innovative cancer treatments. On the clinical front, Crystalys Therapeutics has made waves by securing $130 million in Series B funding, propelling their gout treatment, Dotinurad, into Phase 3 trials. This drug targets uric acid levels, addressing a significant unmet need in gout management. The progression into late-stage trials reflects confidence in Dotinurad's potential to provide effective relief for patients suffering from this painful condition. Regulatory advancements are also making headlines with the UK's MHRA granting approval to Chiesi's Clenil Modulite with a low-carbon propellant for asthma maintenance treatment. This move signifies a crucial step towards more sustainable pharmaceutical practices without compromising efficacy—setting a potential benchmark for future respiratory treatments that incorporate eco-friendly technologies. In business development news, Ashlins Pharmaceuticals and Lee's Pharmaceutical have struck a $31 million licensing deal for interferon alpha-2b outside China, focusing on rare diseases. Similarly, Jupiter Neurosciences' acquisition of MDMA asset ALA-002 from Pharmala Biotech illustrates ongoing interest in small molecule therapeutics for neurological conditions. Royalty Pharma's significant $425 million payment to Neurimmune highlights strategic investments in cardiovascular therapies through royalty financing, underscoring confidence in advancing novel treatments. Concurrently, Dimension has raised an impressive $800 million for an AI-driven biotech drug discovery fund. The integration of AI promises accelerated drug development timelines and enhanced precision in identifying viable candidates. However, not every development is favorable. Celldex Therapeutics faced a setback with their Phase 2 trial failure for barzolvolimab in prurigo nodularis patients. Such challenges highlight the inherent risks associated with innovative drug development. Turning our attention to another scientific milestone, Arrowhead Pharmaceuticals has reported promising Phase 3 data on its triglyceride-lowering drug, Plozasiran. With analysts praising its "best-in-class profile," Arrowhead aims for FDA approval by year-end, setting up potential competition with Ionis Pharmaceuticals' Tryngolza. These advancements underscore significant progress in targeting specific lipid disorders and the promise of novel therapies to improve cardiovascular health. Corporate strategies are also evolving as seen with Sanofi undergoing executive restructuring under new leadership by CEO Belen Garijo. This reflects broader industry trends where leadership shifts align corporate strategies with market demands and scientific opportunities. Legal developments have not gone unnoticed either. Amgen's $74 million settlement over allegations of concealing a substantial tax bill highlights ongoing scrutiny over corporate governance within the sector. Meanwhile, industry giants are rallying around regulatory defenses, as evidenced by biopharma companies supporting the FDA amidst legal challenges concerning mifepristone—a move emphasizing the industry's vested interest in maintaining access to drugs based on scientific merit. From a technological perspective, companies are increasingly adopting connected trial technologies to streamline processes such as consent and reporting—advancements crucial for reducing patient burden and accelerating drug development timelines. In conclusion, these developments portray an industry at the forefront of scientific innovation while navigating complex regulatory environments and ethical considerations. As firms continue exploring novel treatment avenues and leveraging technological advancements like AI, they position themselves for transformative impacts on patient care and global health outcomes. We look forward to keeping you updated on these exciting trends shaping the future of pharma and biotech industries.Support the show

There's a lot of great innovation happening, but it can be frustrating how long it takes for products to hit the market.

Dan Romero, who leads go-to-market at Tempo, joins Sam Ewen with a 12-year crypto perspective that stretches from the early days at Coinbase to building Farcaster to now focusing entirely on stablecoin payment rails. He breaks down why these three things: regulation, infrastructure, and distribution, have finally aligned to make real world crypto adoption possible, and why Tempo's betting on being the best payments chain rather than a general purpose blockchain. - Timecodes: 0:00 – Intro on stablecoin yield philosophy 1:20 – From Farcaster to Tempo: the through line 2:56 – The market split: speculation vs. stablecoins 5:37 – Regulatory tailwinds from the Genius Act 8:41 – How yield on Tempo works 14:23 – Balancing privacy and transparency 17:38 – What it takes to win in payments infrastructure 21:01 – Why compliance matters 22:25 – Outlook on the Genius Act rulemaking - From our sponsors: Ledn provides a secure and transparent way to access liquidity while maintaining your bitcoin holdings. Perfect 8 year track record of keeping clients assets safe. Don't sell your bitcoin. Get a bitcoin-backed loan. Check out your rate by using their loan calculator at ledn.io - This episode is brought to you by RealFi, a smarter stablecoin, backed by real-world assets. Find out more at realfi.co. - Check out CoinDesk Research's report on Zcash's push toward private scale and quantum resilience at: https://www.coindesk.com/research/building-the-zcash-machine-tachyon-and-quantum-readiness - "Spotlight" features host Sam Ewen.

Anika sits down with Dr. Tommy Rhee, a former US Navy aviator, sports chiropractor, and founder of RheeGen. They discuss his journey from treating professional athletes and Olympians to developing a patent-pending, topical stem-cell cream. Dr. Rhee shares why he shifted away from injectables, the challenges of self-funding a biotech startup, and his bold transition toward plant-based regenerative medicine to make advanced healing affordable and accessible for everyone.In This EpisodeHow a Navy aviator background shapes startup discipline and problem-solvingThe pivot from traditional sports chiropractic care to pioneering topical regenerative medicineWhy elite athletes avoid downtime and how that inspired a non-invasive solutionThe science behind stem cell signals (extracellular vesicles) and transdermal deliveryTransitioning from human-tissue stem cells to plant-based alternatives for cost and accessibilityThe challenges of self-funding a biotech company and seeking proof of conceptWhy writing a book (The Future of Regenerative Medicine) became the ultimate patient education toolTimestamps00:00 Introduction: Meet Dr. Tommy Rhee and the mission of RheeGen 01:28 How Navy aviation training translates to biotech entrepreneurship 04:50 From sports fanatic to treating professional athletes and Olympians 09:04 The problem with athlete recovery, pain management, and forced downtime 10:10 A pivotal moment with a pro quarterback that inspired topical stem cell therapy 17:16 Balancing an active chiropractic practice while self-funding a biotech startup 18:33 The game-changer: Sourcing regenerative signals from plants instead of human tissue 24:40 Why Dr. Rhee wrote his book before launching his consumer product 28:04 Regulatory hurdles and the ethical supply chain issues in traditional stem cell clinics 31:46 The stress and reward of delivering a TEDx talk on healthcare breakthroughs 36:15 Democratizing sports medicine: Making elite healing accessible to the everyday person 41:19 Favorite quote: Bruce Lee's "Be like water"Key Insights & TakeawaysInsight 1: Focus on Micro-Victories Drawing from his Navy aviation background, Dr. Rhee emphasizes the importance of breaking massive goals down into actionable steps. R&D and business development don't happen overnight; they are the result of small, consistent wins that build momentum, test hypotheses, and create confidence.Insight 2: The Needle is the Problem Traditional regenerative medicine relies on injectables, which create secondary injury sites, pose infection risks, and require downtime that professional athletes can't afford. Topical delivery solves these pain points by offering non-invasive, transdermal healing that can be applied seamlessly during a competitive season.Insight 3: It's About the Signal, Not the Cell Live stem cells themselves aren't the magic bullet—it's the information (extracellular vesicles or EVs) they secrete. Once Dr. Rhee understood that healing relies on signaling existing tissue to regenerate, he realized those smaller molecules could be effectively delivered via a transdermal cream.Insight 4: Plant-Based is the Future of Accessible Healing Human-tissue stem cells are expensive, highly regulated, and limited in supply, which has led to shady practices in the industry. By identifying plants that emit the exact same regenerative signals as human tissues, RheeGen is pivoting to an Over-The-Counter (OTC) model that aims to bring the cost of elite therapy under $100.Insight 5: Educational Content as a Business Strategy Dr. Rhee didn't wait until his product was fully mainstream to establish thought leadership. Writing a book and doing a TEDx talk allowed him to educate the market, establish trust, and replace repetitive 40-minute patient consultations with a scalable, accessible educational resource.Resources & Links MentionedCompany: RheeGen (Topical Regenerative Medicine)Book: The Future of Regenerative Medicine by Dr. Tommy RheeVideo: Dr. Tommy Rhee's TEDx Talk (Science fiction inspiring healthcare)About Dr. Tommy RheeDr. Tommy Rhee is a former US Navy aviator, the former team chiropractor for the Tampa Bay Buccaneers, and the founder and CEO of RheeGen. After years of treating elite athletes, WWE wrestlers, and Olympians, he saw the limitations and exorbitant costs of traditional injectable regenerative medicine. This frustration inspired him to develop a patent-pending topical therapy. He is also a bestselling author and TEDx speaker passionate about democratizing sports medicine and making advanced healing accessible to the everyday weekend warrior.Connect with Dr. Tommy RheeWebsite: www.RheeGen.comLinkedIn: https://www.linkedin.com/in/drtommyrhee/Facebook: RheeGenSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent advancements in these sectors highlight a fascinating intersection of technology and medicine, underscoring a push towards innovation that promises to reshape healthcare delivery. Bristol Myers Squibb has expanded its collaboration with NVIDIA, aiming to create what could become the most powerful AI infrastructure dedicated to life sciences. This partnership is set to harness artificial intelligence and machine learning technologies to revolutionize drug discovery and development. By enhancing data analysis and predictive modeling, this collaboration may lead to more efficient identification and validation of drug targets, reflecting a growing industry trend towards leveraging AI to streamline R&D processes. In infectious diseases, Gilead Sciences and Merck & Co. have reported promising phase 3 clinical trial results concerning their combination therapy for HIV treatment. This regimen, combining islatravir and lenacapavir, could become the first weekly oral medication for HIV, offering a significant improvement over daily treatments. Such developments not only promise enhanced patient adherence but also mark a pivotal step forward in long-term HIV management by potentially increasing quality of life for patients. Oncology diagnostics are also seeing significant strides as Tempus AI plans to acquire Personal Genome Diagnostics for $1.5 billion. This acquisition is poised to bolster Tempus's portfolio in cancer minimal residual disease diagnostics. The integration of capabilities from Personal Genome Diagnostics is expected to enhance precision oncology efforts, providing more comprehensive data for personalized cancer treatment plans. Regulatory updates bring more promising news with Takeda's dengue vaccine, Qdenga, securing approval in India. This live-attenuated vaccine targets all four serotypes of the dengue virus, representing a major advancement in regions burdened by dengue fever. Similarly, JCR Pharmaceuticals has received marketing authorization in the UAE for Izcargo, an enzyme replacement therapy that penetrates the blood-brain barrier to treat Hunter syndrome, showcasing innovations in treating rare genetic disorders. Strategic partnerships continue to be a focal point in industry growth. Menarini Asia-Pacific has joined forces with Pharmacosmos to commercialize Cosela across Asia-Pacific regions. Additionally, Halozyme Therapeutics has partnered with Incyte on subcutaneous formulations of a monoclonal antibody using their proprietary Enhaze technology, highlighting advancements in drug delivery systems. Financially, Novartis has shown resilience by returning to sales growth driven by products like Kisqali and Kesimpta amidst generic competition challenges. Meanwhile, Axiom Biosciences is gearing up for an IPO in Hong Kong, indicating a growing interest in stem cell therapies for neurological and rare diseases. Yet not all news has been positive. Novartis has discontinued its phase 2 radioligand therapy targeting gastrin-releasing peptide receptors due to underwhelming results in solid tumors. Agios Pharmaceuticals has similarly halted development of its pyruvate kinase activator for sickle cell disease following unsatisfactory phase 2 data. Legal battles continue as well, with Novo Nordisk suing Eli Lilly over GLP-1 agonists efficacy claims and Moderna locked in patent disputes with CureVac over COVID vaccine technologies. These stories reflect dynamic shifts emphasizing innovation through AI collaborations and novel therapeutic developments in HIV and oncology treatments. They also highlight strategic acquisitions enhancing diagnostic capabilities while revealing challenges such as competitive pressures and regulatory hurdles that companies must navigate. Turning our attention back to scientific breakthroughs, Jennifer Doudna's venture into AI-powered protein design underscores how artificial intelligence continues transforming biotechnology. Her exploration highlights AI's potential to accelerate drug discovery by enabling more precise targeting of disease-related proteins. Additionally, recent successes in personalized medicine include the establishment of a new center dedicated to genetic therapies. Spearheaded by leading scientists, this initiative aims at developing tailored treatments based on individual genetic profiles—advancing precision medicine and reducing adverse effects. In conclusion, these developments illustrate a vibrant landscape where scientific breakthroughs intersect with strategic business maneuvers. As companies navigate these complex waters—balancing innovation with regulatory scrutiny—they continue pushing boundaries that promise improved patient outcomes worldwide while reshaping future healthcare landscapes.Support the show

Aligned Climate Capital's Peter Davidson discusses how state regulatory regimes guide growth of the distributed generation sector.

The squeeze is on.Federal enforcement is intensifying, with behavioral health agencies facing heightened scrutiny following revealing reports from the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG). According to the OIG, there have been numerous fraud cases involving false claims and falsified documentation.But among this emerging sturm und drang, there is a critical role that health information management (HIM) can play – as you and your team will learn during the next live edition of Talk Ten Tuesdays. That's when special guest Veronica Richardson, senior compliance consultant at First Class Solutions, will discuss how HIM can play a significant role in behavioral health compliance.The popular weekly Internet broadcast will also feature these additional instantly recognizable panelists, who will report more news during their segments:• POV: Penny Jefferson, Manager of Coding & Clinical Documentation Integrity Services for the University of California-Davis Medical Center, will share her point of view during the broadcast.• CDI Report: Cheryl Ericson will provide an update on all things clinical documentation integrity (CDI).• SDoH Report: Tiffany Ferguson will report on news happening at the intersection of compliance and medical record coding.• The Coding Report: Christine Geiger will report on the latest coding news.

This bonus episode expands on the themes discussed in Episode 5 by providing a practical example of how energy resilience strategies are implemented at the local level. The discussion focuses on Switzerland's requirements for large energy consumers, organisations that exceed defined thresholds for electricity or heat consumption and are therefore subject to specific obligations to improve energy efficiency and reduce emissions. The guests explain the regulatory pathways available, including target agreements, energy audits, and cantonal agreements, highlighting how requirements can vary across Switzerland's 26 cantons. Ultimately, the case study reinforces a central theme of the series: global challenges require locally informed solutions, and energy resilience depends on balancing regulatory compliance, operational efficiency, and long-term sustainability goals. Guest quotes: Mariarosaria Gagliotti: “By meeting the definition of a large energy consumer, the company is obligated to take action, implementing reasonable measures to optimise energy consumption.” Sofiane Kessouar: “The LEED certification provides a framework for designing, constructing and operating highly efficient and cost-saving green buildings.” Timestamps: 00:00:00 – Introduction to the Swiss energy resilience case study 00:01:11 – Defining large energy consumers in Switzerland 00:02:13 – Legal obligations for energy efficiency and emissions reduction 00:02:31 – Regulatory compliance pathways and available options 00:03:31 – Choosing the most appropriate compliance strategy 00:04:09 – Single-site versus multi-site considerations 00:04:54 – Understanding Switzerland's cantonal structure 00:05:22 – Local regulations and sustainable construction leadership 00:05:55 – Introduction to LEED certification 00:06:31 – Benefits of green building standards 00:07:06 – Key LEED certification categories 00:07:39 – Lower operating costs and environmental benefits 00:07:57 – Reflections on local expertise and real-world case studies 00:08:06 – Closing remarks and the value of global collaboration Sponsor Copy Rethinking EHS is brought to you by the Inogen Alliance. Inogen Alliance is a global network of 70+ companies providing environment, health, safety, and sustainability services, working together to provide one point of contact to guide multinational organizations to meet their global commitments locally. Visit inogenalliance.com to learn more. --- Links https://Inogenalliance.com/resources https://Inogenalliance.com/podcast Produced by Madcontent.co.nz  

In this episode, Alexander Cutler, CEO of Dromos Labs, shares insights on DeFi, Layer 2 solutions, and the future of on-chain finance, focusing on the success of Aerodrome and Velodrome on Base and Ethereum. Discover how strategic choices and innovative tokenomics are shaping the future of decentralized exchanges and the broader on-chain economy.Check Out Scribe: Scribe.how/CRYPTO101Check out Quince: https://quince.com/CRYPTO101Check out Shopify: https://shopify.com/crypto101Check out NPR: https://npr.orgGet my #1 altcoin pick for this month.Get immediate access to my entire crypto portfolio for just $1.00 today! Get your FREE copy of "Crypto Revolution" and start making big profits from buying, selling,Get immediate access to my entire crypto portfolio.. just $1.00 today! Go here to get access: https://www.crypto101insider.com/cryptnation-directm6pypcy1?utm_source=Internal&utm_medium=YouTube&utm_content=Podcast&utm_term=20250916Get your FREE copy of "Crypto Revolution: Your Guide To The Future of Money". In this book, I reveal how to make (and keep) a fortune during this crypto bull run! http://www.cryptorevolution.com/free?utm_source=Internal&utm_medium=YouTube&utm_content=Podcast&utm_term=20250916Chapters00:00 Introduction and guest background01:30 The evolution of Dromos Labs and platform choices04:00 Alexander's journey into crypto and DeFi07:00 Success story of Velodrome and Aerodrome on Optimism and Base14:05 The strategic focus on Base and Ethereum17:49 Layer 2 solutions and their role in Ethereum's future23:03 The vision of 10% of global GDP on-chain28:01 Regulatory clarity and institutional adoption34:01 Security, decentralization, and protocol design46:58 The Aero tokenomics and revenue flywheel53:57 Upcoming updates and closing remarksSubscribe to YouTube for Exclusive Content:https://www.youtube.com/@crypto101podcast?sub_confirmation=1Follow us on social media for leading-edge crypto updates and trade alerts:https://twitter.com/Crypto101Podhttps://instagram.com/crypto_101*This is NOT financial, tax, or legal advice*Boardwalk Flock LLC. All Rights Reserved  ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Fog by DIZARO https://soundcloud.com/dizarofrCreative Commons — Attribution-NoDerivs 3.0 Unported — CC BY-ND 3.0 Free Download / Stream: http://bit.ly/Fog-DIZAROMusic promoted by Audio Library https://youtu.be/lAfbjt_rmE8▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Our Sponsors:* Check out NPR: https://npr.org* Check out Quince and use my code quince.com/crypto101 for a great deal: https://www.quince.com* Check out Scribe and use my code Scribe.how/CRYPTO101 for a great deal: https://scribe.com/Crypto101* Check out Shopify and use my code shopify.com/crypto101 for a great deal: https://www.shopify.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this episode of Medsider Radio, we sat down with Bob Paulson, President and CEO of Sonex Health. Sonex's UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Bob Paulson, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:19) - Bob's path from Medtronic to multiple medtech exits before joining Sonex (05:38) - Why 80% of eligible carpal tunnel patients avoid surgery — and how Sonex is changing that (11:11) - The reimbursement challenge that reshaped Sonex's clinical evidence strategy (19:07) - Reimbursement is a three-leg process: FDA, CPT, and payer coverage (22:07) - Reverse engineering your company from the exit you're trying to achieve (29:35) - How Sonex helped surgeons move carpal tunnel procedures out of the OR (39:06) - Sonex's "pitcher-catcher" approach to physician and patient adoption (41:59) - Bob's framework for choosing investors who can finance the entire journey, not just the next round

Recorded live at the inaugural edition of Fintech Nerdcon in Miami, Florida, Eyal is joined by Alex Johnson, the Founder of Fintech Takes, one of the most widely-read publications in the fintech industry. The United States' first real attempt at regulating open banking, known as Section 1033, has been anything but smooth; challenged on day one, declared unlawful, and stuck in court-ordered limbo. At the center of that chaos sits a deeper fight over who controls personal financial data and who gets to profit from it. Eyal and Alex dig into what this turbulence reveals, not just about America's uniquely chaotic path to open banking, but about the questions every market must eventually face around standards, cost recovery and trust, questions which only grow more urgent as agentic AI enters the picture. Ultimately, this leads to the biggest question of all, one that reaches far beyond open banking: How do we create a world where we have the right to control our own data? Specifically they discuss:Regulatory chaos in the U.S.Charging fees for data accessThe role of shared standardsAgentic AI and open banking The future of data rights

Dr. ⁠Basant Bajpai⁠ CEO of ⁠Compliance MedQRA⁠, a UAE-based consulting company specializing in Quality Assurance, Regulatory Affairs, AI governance and compliance for medical devices, SaMD, AI/ML health technologies and digital health solutions. He holds a PhD in Neuroscience focused on brain monitoring and neurotechnology and has more than 12 years of international experience supporting MedTech and digital health companies across Europe, the Middle East and the United States.He explains why regulatory and quality is still one of the most misunderstood functions in MedTech and why so many innovators treat it as a documentation exercise until it becomes an expensive problem at the worst possible moment. We get into the question every founder asks, how long will this take and what will it cost and why there is genuinely no straight answer without first building a proper regulatory strategy.We also tackle the growing trend of companies choosing the US over EU MDR simply because it looks faster. Basant makes the case that regulatory approval alone does not guarantee commercial entry, why reimbursement codes should shape your market choice more than approval timelines and why he now finds EU MDR more convenient than many people expect. He also shares a contrarian view on device classification and why staying in the lowest risk class is not always the smart play.Finally, we explore the GCC regulatory landscape, which Basant argues is not less regulated but differently regulated, with data compliance requirements he found tougher than GDPR or HIPAA. He closes with a clear message on AI in healthcare and why he does not believe regulators will ever allow a clinician to be replaced.Timestamps[00:01:23] From Biomedical Engineering to a First Audit That Changed Everything[00:03:33] Why Everyone Thinks Regulatory Is Just a Documentation Department[00:06:07] How Long Will It Take and What Will It Cost: The Impossible Question[00:09:35] EU MDR vs FDA: Why Reimbursement Should Drive the Decision[00:12:19] Regulatory Approval Does Not Guarantee Commercial Success[00:14:36] Why Staying in the Lowest Risk Class Can Backfire[00:16:00] The GCC: Not Less Regulated, Just Differently Regulated[00:18:24] Why Data Compliance in the Gulf Is Tougher Than GDPR[00:23:30] Who Should Not Pursue a Career in Quality and Regulatory[00:29:17] Final Advice: AI Will Transform Healthcare but Not Replace CliniciansConnect with Basant - https://www.linkedin.com/in/basant-bajpai-phd-63565961Learn more about Complaince MedQRA - https://www.compliancemedqra.net/Get in touch with Karandeep Badwal - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/karandeepbadwal/ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Karandeep on YouTube - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@KarandeepBadwal⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medical device training courses delivered by Karandeep through Bywater - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.bywater.co.uk/

Join hosts Paul Nathanson, Caitlin Sickles, and Omar Nashashibi as they discuss the sudden passing of Senator Lindsey Graham, his legacy, and his unique ability to be one of the few lawmakers who consistently had the president's ear. The team also examines Republican efforts to advance Reconciliation 3.0 and breaks down key items in the White House's latest regulatory agenda affecting manufacturers.

Who would have thought that the otherwise fairly simple Medicare Cost Report could be a serious compliance trap?Some are calling the new Medicare report worksheet a possible precursor to the most significant reimbursement change in decades.For 2026, the Centers for Medicare & Medicaid Services (CMS) will require hospitals to report Medicare Advantage (MA)-negotiated reimbursement by Medicare Severity Diagnosis-Related Group (MS-DRG).The implications extend far beyond compliance, requiring coordination across reimbursement, finance, revenue cycle, managed care, coding, IT, and analytics.Listen and learn during the next edition of Monitor Mondays when the CEO for Panacea Healthcare, Kevin Chmura, unpacks Worksheet S-12. You'll quickly discover the finer details of the looming fundamental shift toward market-based reimbursement, and how forward-thinking hospitals can turn this change into a strategic advantage.Broadcast segments will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Matthew Albright, chief legislative affairs analyst for Zelis, will report on current healthcare legislation.

More on VPM.org:  NextEra–Dominion merger filings start 6-month clock on regulatory review  Mending a torn safety net: an investigation into Nelson County social services    Other links:  Report finds ‘substantial disparities' in Virginia Beach contracts with minority-owned businesses (Virginian-Pilot)*  How a Roanoke school's new playground is neurodevelopmentally inclusive (Roanoke Times)*  House committee questions Va. prosecutor in closed-door deposition (Washington Post)*  About time? Richmonders weigh-in on possible permanent daylight saving time (WTVR)  GOP Senate hopefuls face long odds in race to challenge Mark Warner (Virginia Mercury)  Mending a torn safety net: lagging salaries, lapsed communication at Nelson DSS (WMRA)  Mending a torn safety net: systemic challenges in social services (WMRA)  *This outlet uses a paywall.  Our award-winning work is made possible with your donations. Visit vpm.org/donate to support local journalism. 

In this episode of the Gladden Longevity podcast, Dr. Gladden interviews Shaun Noorian from Empower Pharmacy, discussing the growth and mission of the pharmacy, the cost-effectiveness of compounding medications, quality standards in compounding, regulatory oversight, and the ongoing controversy surrounding peptides and FDA decisions. The conversation highlights the importance of personalized medicine and the challenges faced by compounding pharmacies in providing affordable and effective treatments for patients. In this conversation, Dr. Gladden and Shaun Noorian discuss the evolving landscape of compounding pharmacies and personalized medicine. They explore the regulatory challenges faced by compounding pharmacies, the promise of new medications like retatrutide, and the role of GLP-1s in health management. The discussion highlights the importance of muscle preservation in weight loss therapies and the advocacy needed to ensure patient access to compounded medications. They emphasize the renaissance of compounding in healthcare, which is making treatments more accessible and affordable for patients.   For Audience Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now   Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!     Takeaways ·       Empower Pharmacy has been operational for 17 years and focuses on personalized medicine. ·       Compounding pharmacies are becoming more popular due to their cost-effectiveness compared to commercial options. ·       Quality standards in compounding are well-established and continuously updated. ·       Compounding pharmacies are subject to rigorous regulatory oversight and inspections. ·       The FDA is currently reviewing the status of several peptides for compounding. ·       Recent changes in the FDA advisory committee may impact the approval of new compounds. ·       The conversation emphasizes the need for evidence-based decisions in healthcare. ·       Dr. Gladden highlights the discrepancies in drug approvals and their implications for patient care. ·       The black market for peptides poses significant risks to patient safety. ·       The discussion underscores the importance of maintaining high-quality standards in compounding pharmacies. The FDA's decisions will significantly impact compounding pharmacies. ·       Compounding pharmacies ensure medication integrity and safety. ·       Personalized medicine is expanding into various health areas. ·       Regulatory challenges hinder the compounding of certain medications. ·       Retatrutide is expected to revolutionize weight loss therapies. ·       GLP-1s have multiple health benefits beyond weight loss. ·       Weight loss therapies can lead to muscle loss, complicating health outcomes. ·       Innovative alternatives to GLP-1s are emerging in the market. ·       Compounding pharmacies play a crucial role in patient access to medications. ·       Advocacy against pharmaceutical monopolies is essential for patient care.    Chapters 00:00 Empower Pharmacy's Growth and Mission 03:01 Cost-Effectiveness of Compounding Pharmacies 06:00 Quality Standards in Compounding 08:54 Regulatory Oversight and Compliance 12:01 The Peptide Controversy 15:03 The Impact of FDA Decisions on Patient Care 18:21 The Future of Compounding Pharmacies 20:09 Expanding Areas of Personalized Medicine 21:11 Regulatory Challenges in Compounding 22:04 The Promise of Retatrutid 23:39 The Role of GLP-1s in Health 25:02 The Impact of Weight Loss Therapies 26:07 Innovative Alternatives to GLP-1s 27:10 The Importance of Muscle Preservation 28:31 The Role of Compounding Pharmacies in Patient Access 30:16 Advocacy Against Pharmaceutical Monopolies 32:20 Navigating Regulatory Landscapes 34:14 The Renaissance of Compounding in Healthcare   To learn more about Shaun Noorian:Email: media@Empowerpharmacy.com Website: https://www.empowerpharmacy.com/ Instagram: https://www.instagram.com/empowerpharmacy   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

For many medical device startups, obtaining FDA clearance seems like a clear, linear process.Identify a predicate device.Prepare your documentation.Submit your application.Wait for clearance.In reality, the journey is rarely that simple.In this episode of the Medical Device Made Easy Podcast, Joanna Nathan, CEO of Prana Surgical, shares her firsthand experience navigating the FDA clearance process and discusses the challenges that many startups only discover after they begin.Topics CoveredThe Reality Behind FDA ClearanceWhen do founders realize the process is more complex than expected?What would they do differently if they could start again?Predicate Devices and Substantial EquivalenceChoosing the right predicate device is one of the most important strategic decisions in a 510(k) submission.We discuss:Predicate device selectionIntended use considerationsTechnological characteristicsCommon misconceptions about substantial equivalenceBuilding a Product with the FDA in MindThe conversation explores how early regulatory decisions influence:Product developmentTesting strategyDocumentationRisk managementManufacturing planningWorking with the FDAHow valuable are Pre-Submission (Q-Sub) meetings?What questions should manufacturers ask?What mistakes should they avoid before engaging with the FDA?Lessons Every Startup Should KnowJoanna shares practical advice on:Unexpected FDA questionsCommon causes of delaysSoftware validationBiocompatibilityUsability studiesDocumentation preparationThe biggest misconceptions surrounding FDA clearanceKey TakeawayFDA clearance is much more than completing regulatory paperwork.Successful companies integrate regulatory thinking into product development from the very beginning.Making the right strategic decisions early can save significant time, reduce costs, and improve the likelihood of a successful FDA submission.Whether you're launching your first medical device or preparing your next regulatory submission, this episode provides practical insights to help you navigate the FDA clearance journey with greater confidence.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkJoanna's LinkedIn: https://www.linkedin.com/in/joannacnathanPrana System: https://www.pranasurgical.com/prana-systemPrana Surgical's LinkedIn: https://www.linkedin.com/company/pranasurgicalSocial Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Curious about a flexible, high-paying nonclinical career that still uses your medical expertise? In this episode, I'm joined by Dr. Keagen Hadley, an occupational therapist who built a successful career in regulatory medical writing without ever stepping into clinical practice. Dr. Hadley shares how he discovered this little-known field while working in clinical research, the persistence it took to break in, and why regulatory writing can be such an appealing option for physicians seeking flexibility, meaningful work, and strong earning potential. We also explore what regulatory writers actually do, who tends to thrive in this role, how AI is impacting the profession, and practical strategies for getting started. If you enjoy structure, attention to detail, and helping bring new therapies to patients, this conversation may open your eyes to an exciting career path you hadn't considered. In this episode we're talking about: What regulatory medical writing is and its role in drug, biologic, and device development The personality traits and skills that help people succeed in regulatory writing Dr. Keagen Hadley's unconventional path from occupational therapy to a thriving writing career How physicians can break into the field through networking, recruiters, and strategic positioning Compensation, flexibility, and career growth opportunities in regulatory writing How AI is influencing regulatory writing and why human expertise remains essential Resources, training recommendations, and practical advice for exploring this career path You can find the show notes for this episode and more information by clicking here: www.doctorscrossing.com/episode251 Links for this episode: The Clinician's Guide to Regulatory Writing | Keagen Hadley | Substack  Keagen Hadley | LinkedIn  Targeted Regulatory Writing Techniques: Clinical Documents for Drugs and Biologics by Wood and Foote 6 Month Road Map to Becoming a Regulatory Writer by Keagen Hadley Regulatory Medical Writing Masterclass  Medical Writing Resource Guide – This 11-page guide gives you an introduction to medical writing as well as links for courses, books, websites, and tips for exploring this diverse area. Includes steps you can take whether you want to do medical writing as a side gig, or work full-time as a freelancer or an employee. Land Your Dream Job With LinkedIn: 5 Steps To Get Started – Following these 5 tips will help you optimize your profile, connect and network with others, and have success applying to jobs on LinkedIn! Thank you for listening!

(1) Regulatory Certitude in Londinium: The Power of the Building Inspector and Beachfront Evictions Guests in Londinium, 92 AD: Gaius and Germanicus. The show is temporarily halted due to occupancy issues at the wine bar. Gaius admits to a "completely unforgivable error": failing to give the building inspector an annual birthday raise. He notes that even far from Rome, the local inspector's "red ticket" carries enough weight to shut down their beachfront wine bar despite the Emperor Domitian's distance. The inspector cited concerns about running water, windows, and roof tiles, though Gaius suspects it was a move for more "generous gifts." He laments that his focus on a "robot" sent from Chinafor the orchestra caused him to neglect the inspector's welfare. The hosts plan a "great big party" with the help of centurions to scrub the facility and restore order for the following week's broadcast. (1)londinium 1682 ad

(3) The Phony War and Strategic Reserves: Regulatory Displacement, the Iran-US "Phony War," and the Doctrine of Unconditional Surrender Guests in Londinium, 92 AD: Gaius and Germanicus. Broadcasting a "bootleg edition" from a parking lot after being forced out by the building inspector, the hosts discuss the unsustainable nature of the escalating US-Iran conflict. Gaius compares the current "drip drip" of hostilities to the minor-sounding reports from 1938–1939, questioning the sustainability of these incremental escalations. Germanicus frames the conflict as a "Sitzkrieg" or "phony war," noting that unlike 1940, the current pressure is the depletion of strategic oil reserves — the crisis isn't "instantly imminent," but the drawdown makes it temporary. He critiques the American "neuralgia" of demanding unconditional surrender, an unattainable goal he traces from the Civil War to modern leaders like Trump and Biden, arguing that a military tradition requiring demonized enemies and total submission prevents realistic resolutions. They conclude that the current diplomatic and military path is a "will-o'-the-wisp" that cannot be achieved through air power or Blitzkrieg. (3)1945 BBERLIN